TNO155 Plus Spartalizumab or Ribociclib Elicits Disease Control, Is Safe in Advanced Solid Tumors

TNO155 plus spartalizumab or ribociclib was well tolerated and demonstrated disease control in patients with advanced solid tumors.

Related Keywords

Spain ,Hebron ,Israel General ,Israel ,Barcelona ,Comunidad Autonoma De Cataluna ,Omar Saavedra ,Anticancer Therapies Congress ,Hebron Institute Of Oncology ,Early Drug Development Unit ,Anticancer Therapies ,Hebron Institute ,Smo Targeted Anticancer Therapies Congress ,News ,Conference ,Solid Tumors ,Tno155 ,Spartalizumab ,Ribociclib ,